FATE THERAPEUTICS INCFATEEarnings & Financial Report
Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.
Revenue
$1.9M
Gross Profit
N/A
Operating Profit
$-51.1M
Net Profit
$-48.0M
Gross Margin
N/A
Operating Margin
-2652.9%
Net Margin
-2493.7%
YoY Growth
-96.7%
EPS
$-0.47
FATE THERAPEUTICS INC Q1 FY2024 Financial Summary
FATE THERAPEUTICS INC reported revenue of $1.9M (down 96.7% YoY) for Q1 FY2024, with a net profit of $-48.0M (down 154.2% YoY) (-2493.7% margin).
Key Financial Metrics
| Total Revenue | $1.9M |
|---|---|
| Net Profit | $-48.0M |
| Gross Margin | N/A |
| Operating Margin | -2652.9% |
| Report Period | Q1 FY2024 |
FATE THERAPEUTICS INC Annual Revenue by Year
FATE THERAPEUTICS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $6.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $6.6M |
| 2024 | $13.6M |
| 2023 | $63.5M |
| 2022 | $96.3M |
FATE THERAPEUTICS INC Quarterly Revenue & Net Profit History
FATE THERAPEUTICS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.4M | -26.4% | N/A | N/A |
| Q3 FY2025 | $1.7M | -43.4% | $-32.3M | -1852.4% |
| Q2 FY2025 | $1.9M | -71.8% | $-34.1M | -1786.6% |
| Q1 FY2025 | $1.6M | -15.4% | $-37.6M | -2309.5% |
| Q4 FY2024 | $1.9M | +11.0% | N/A | N/A |
| Q3 FY2024 | $3.1M | +58.1% | $-47.7M | -1551.0% |
| Q2 FY2024 | $6.8M | +625.8% | $-38.4M | -567.4% |
| Q1 FY2024 | $1.9M | -96.7% | $-48.0M | -2493.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $6.8M | $3.1M | $1.9M | $1.6M | $1.9M | $1.7M | $1.4M |
| YoY Growth | -96.7% | 625.8% | 58.1% | 11.0% | -15.4% | -71.8% | -43.4% | -26.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $569.9M | $528.8M | $495.0M | $440.7M | $398.7M | $371.6M | $343.7M | $318.9M |
| Liabilities | $143.8M | $131.8M | $132.6M | $122.0M | $110.3M | $110.3M | $109.6M | $111.8M |
| Equity | $426.1M | $397.0M | $362.3M | $318.7M | $288.4M | $261.4M | $234.1M | $207.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-33.4M | $-32.3M | $-29.4M | $-122.9M | $-33.8M | $-24.6M | $-24.4M | $-106.1M |